Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation

Blood (2023) 142 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2023-184951

Published: 2023

Journal Articles

Dose Escalation Study of GCC19CART CoupledCAR ® Technology for Patients with Relapsed or Refractory Colorectal Cancer

Naifei Chen, Chengfei Pu, Lingling Zhao, Chang Wang, Ruihong Zhu, Tingting Liang, Xi Huang, Haiyang Tang, Yizhuo Wang, Beibei Jia, Dongqi Chen, Eugene Kennedy, Zhao Wu, Lei Xiao, Jiuwei Cui

Blood (2021) 138 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2021-153429

Published: 2021

Journal Articles

CoupledCAR TM Technology for Treating Thyroid Cancer

Xingchen Liu, Lei Xiao, PhD, Keshu Zhou, Yu Liu, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu

Blood (2020) 136 (Supplement 1): 46.

https://doi.org/10.1182/blood-2020-138668

Published: 2020

Journal Articles

Novel CoupledCAR TM Technology for Treating Colorectal Cancer

Lei Xiao, PhD, Song Li, Chengfei Pu, Zhiyuan Cao, Xinyi Yang, Ning Li, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiuwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu

Blood (2020) 136 (Supplement 1): 54.

https://doi.org/10.1182/blood-2020-140653

Published: 2020

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3047.

https://doi.org/10.1182/blood-2019-131025

Published: 2019

Journal Articles

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Ruyi Xu, Yi Li, MD, Haimeng Yan, MD, Xi Huang, MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2019) 134 (Supplement_1): 3086.

https://doi.org/10.1182/blood-2019-126498

Published: 2019

Journal Articles

Multiple Myeloma Cell-Derived Interleukin-32gamma Increases the Immunosuppressive Function of Macrophages By Promoting Indoleamine 2,3-Dioxygenase (IDO) Expression

Haimeng Yan, Donghua He, Xi Huang, MD, Zhang En Fan, He Huang, MD, Zhen Cai, MD PhD

Blood (2018) 132 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2018-99-114316

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

Haimeng Yan, Xuanru Lin, MD, Xi Huang, MD, Zhang En Fan, Donghua He, Xu Ruyi, Huiyao Gu, Yi Li, MD, Jingsong He, MD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1781.

https://doi.org/10.1182/blood.V130.Suppl_1.1781.1781

Published: 2017

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

Journal Articles

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

Xi Huang, Zhang En Fan, Qingxiao Chen, MS, Haimeng Yan, Xu Ruyi, Xinling Liu, Huiyao Gu, Jingsong He, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1787.

https://doi.org/10.1182/blood.V130.Suppl_1.1787.1787

Published: 2017

Journal Articles

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Jing Chen, M.MD, Donghua He, PhD, Xing Guo, M.MD, Qingxiao Chen, M.MD, Xuanru Lin, M.MD, Jingsong He, Xi Huang, M.MD, Haimeng Yan, Yi Li, PhD, Li Yang, PhD, Yang Yang, PhD, Enfan Zhang, M.MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 4429.

https://doi.org/10.1182/blood.V128.22.4429.4429

Published: 2016

Journal Articles

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Xing Guo, M.MD, Donghua He, PhD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Xi Huang, M.MD, Yi Li, PhD, Li Yang, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2086.

https://doi.org/10.1182/blood.V128.22.2086.2086

Published: 2016

Journal Articles

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib

Xi Huang, M.MD, Enfan Zhang, M.MD, Xing Guo, M.MD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Li Yang, PhD, Yi Li, PhD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2068.

https://doi.org/10.1182/blood.V128.22.2068.2068

Published: 2016

Journal Articles

TET2 Downregulation Promotes AML Cell Proliferation Via Pim-1 Expression

Qingxiao Chen, M.MD, Jingsong He, Xing Guo, M.MD, Jing Chen, M.MD, Xuanru Lin, M.MD, Xi Huang, M.MD, Haimeng Yan, Li Yang, PhD, Yi Li, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 5085.

https://doi.org/10.1182/blood.V128.22.5085.5085

Published: 2016

Journal Articles

Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin

Jeffrey W. Taub, Xi Huang, Larry H. Matherly, Mark L. Stout, Steven A. Buck, Gita V. Massey, David L. Becton, Myron N. Chang, Howard J. Weinstein, Yaddanapudi Ravindranath

Blood (1999) 94 (4): 1393–1400.

https://doi.org/10.1182/blood.V94.4.1393

Published: 1999

NARROW

Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation

Dose Escalation Study of GCC19CART CoupledCAR ® Technology for Patients with Relapsed or Refractory Colorectal Cancer

CoupledCAR TM Technology for Treating Thyroid Cancer

Novel CoupledCAR TM Technology for Treating Colorectal Cancer

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Multiple Myeloma Cell-Derived Interleukin-32gamma Increases the Immunosuppressive Function of Macrophages By Promoting Indoleamine 2,3-Dioxygenase (IDO) Expression

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib Via PTEN/PI3K/Akt Signaling Pathway

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

NEDD4-1 Modulates the Resistance of Multiple Myeloma to Bortezomib

TET2 Downregulation Promotes AML Cell Proliferation Via Pim-1 Expression

Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down Syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only